Show simple item record

dc.contributor.authorPettersen, Solveig
dc.contributor.authorØy, Geir Frode
dc.contributor.authorEgeland, Eivind Valen
dc.contributor.authorJuell, Siri
dc.contributor.authorEngebråten, Olav
dc.contributor.authorMælandsmo, Gunhild Mari
dc.contributor.authorPrasmickaite, Lina
dc.date.accessioned2023-08-17T08:20:18Z
dc.date.available2023-08-17T08:20:18Z
dc.date.issued2023-02-22
dc.description.abstractAssessment of drug sensitivity in tumor tissue ex vivo may significantly contribute to functional diagnostics to guide personalized treatment of cancer. Tumor organoid- and explant-cultures have become attractive tools towards this goal, although culturing conditions for breast cancer (BC) tissue have been among the most challenging to develop. Validation of possibilities to detect concordant responses in individual tumors and their respective cultures ex vivo is still needed. Here we employed BC patient-derived xenografts (PDXs) with distinct drug sensitivity, to evaluate different conditions for tissue dissociation, culturing and monitoring of treatment efficacy ex vivo, aiming to recapitulate the in vivo drug responses. The common challenge of discriminating between tumor and normal cells in the cultured tissue was also addressed. Following conventional enzymatic dissociation of BC tissue, the tumor cells stayed within the non-disrupted tissue fragments, while the single cells represented mostly normal host cells. By culturing such fragments as explants, viable tumor tissue could be maintained and treated ex vivo, providing representative indications on efficacy of the tested treatment. Thus, drug sensitivity profiles, including acquired chemoresistance seen in the PDXs, were recapitulated in the respective explants. To detect the concordant responses, however, the effect monitoring had to be harmonized with the characteristics of the cultured tissue. In conclusion, we present the feasibility of BC explants ex vivo to capture differences in drug sensitivity of individual tumors. The established protocols will aid in setting up an analogous platform for BC patient biopsies with the aim to facilitate functional precision medicine.en_US
dc.identifier.citationPettersen, Øy, Egeland, Juell, Engebråten, Mælandsmo, Prasmickaite. Breast cancer patient-derived explant cultures recapitulate in vivo drug responses. Frontiers in Oncology. 2023;13en_US
dc.identifier.cristinIDFRIDAID 2155574
dc.identifier.doi10.3389/fonc.2023.1040665
dc.identifier.issn2234-943X
dc.identifier.urihttps://hdl.handle.net/10037/30008
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.relation.journalFrontiers in Oncology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleBreast cancer patient-derived explant cultures recapitulate in vivo drug responsesen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)